J B Chemicals & Pharmaceuticals Ltd logo

J B Chemicals & Pharmaceuticals Ltd

JBCHEPHARM NSE

Key Fundamentals

Volatility
High Risk
P/E Ratio
53.33
EBITDA
₹1,168 Cr
Return on Equity
0%
Debt to Equity
0
Book Value
₹0
EPS
₹37.83
52W High
₹2,510
52W Low
₹1,627

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view J B Chemicals & Pharmaceuticals Ltd insights

57 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

4
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 40.3%
  • Promoter holding has increased by 1.25% over last quarter.

Weaknesses

3
  • Stock is trading at 9.30 times its book value
  • Promoter holding has decreased over last 3 years: -5.11%
  • Working capital days have increased from 86.6 days to 126 days

Growth Rate

Revenue Growth
6.36% ↗
Net Income Growth
7.57% ↗
Cash Flow Change
-22.00% ↘
ROE
-11.19% ↗
ROCE
-11.38% ↗
EBITDA Margin (Avg.)
2.59% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 43d ago
AI opinion · based on fundamentals
Risk medium

J B Chemicals & Pharmaceuticals trades at a market cap of ₹39,233 Cr with a PE of 55.2x and PB of 9.4x, reflecting premium valuations. The company has delivered consistent 19% ROE over 3 and 5 years with a near debt-free balance sheet, though TTM sales growth has decelerated to 6% from a 5-year CAGR of 15%.

Bull Case 8
  • Company is almost debt-free, having actively reduced debt, providing financial flexibility for growth investments
  • Consistent ROE of 19% maintained over 1-year, 3-year, and 5-year periods, indicating stable capital efficiency
  • Compounded profit growth of 21% over 3 years outpaces sales growth, reflecting margin expansion and operating leverage
  • Healthy dividend payout ratio of 40.3% signals shareholder-friendly capital allocation and earnings confidence
  • Stock CAGR of 51% over 1 year and 34% over 10 years demonstrates sustained long-term wealth creation
  • Promoter holding increased by 1.25% in the last quarter, signalling insider confidence at current levels
  • 10-year compounded sales CAGR of 13% and profit CAGR of 18% reflect a durable, growing franchise
  • 5-year compounded sales CAGR of 15% places the company among faster-growing mid-cap pharma names
Bear Case 8
  • PE of 55.2x is significantly above the pharma sector average, leaving limited margin of safety if growth disappoints
  • TTM sales growth has decelerated sharply to 6% versus the 5-year CAGR of 15%, raising questions about growth sustainability
  • PB ratio of 9.4x is elevated, meaning much of the future growth is already priced into the stock
  • Working capital days have increased from 86.6 to 126 days, indicating deterioration in cash conversion efficiency
  • Promoter holding has declined by 5.13% over the last 3 years, partially offsetting the recent quarterly increase
  • Dividend yield of just 0.9% offers limited income support relative to the premium valuation being paid
  • The gap between TTM profit growth of 15% and TTM sales growth of 6% may not be sustainable if margin tailwinds fade
  • At 55.2x PE, the stock needs to sustain above-20% profit growth to justify current multiples, a high bar given slowing topline

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 41d ago
Positives 1
  • NCLT approves Torrent Pharma merger Jul 6

    NCLT Ahmedabad sanctioned the amalgamation of J B Chemicals with Torrent Pharmaceuticals. The scheme becomes effective upon RoC filing, consolidating the company into a larger pharma platform.

Neutral 4
  • ₹49.62 Cr block trade on NSE Jul 16

    Approximately 200,031 shares traded at ₹2,480.70 per share in a block deal worth ₹49.62 crores, indicating institutional-level activity.

  • No encumbrance on JBCHEPHARM shares Jul 2

    Torrent Pharmaceuticals declared no encumbrance on J B Chemicals shares for FY26 under SEBI (SAST) Regulations.

  • Senior executives retire Jun 30 Jun 30

    Pradeep Kumar Singh and Suresh Bhise retired from the company effective June 30, 2026, ceasing to be senior management personnel.

  • 50th AGM held with 4 resolutions Jun 17

    J B Chemicals held its 50th AGM on June 17, 2026, with four ordinary resolutions placed for shareholder approval.

TL;DR: J B Chemicals is in the final stages of being absorbed into Torrent Pharmaceuticals, with NCLT approval already secured. There are no notable headwinds in recent news, and institutional block deal activity suggests orderly positioning ahead of the merger completion. The stock's trajectory is now largely tied to the Torrent Pharma integration timeline and RoC filing.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
762
896
882
845
862
1,004
1,001
963
949
1,094
1,085
1,065
904
Expenses
599
664
638
621
664
724
730
709
723
793
775
769
703
Operating Profit
164
232
244
223
198
280
271
255
226
301
310
296
201
OPM %
21%
26%
28%
26%
23%
28%
27%
26%
24%
28%
29%
28%
22%
Other Income
5
6
8
7
17
6
10
8
14
15
15
18
-15
Interest
14
12
10
12
9
6
2
3
1
1
1
2
1
Depreciation
32
31
32
34
41
41
42
42
46
43
44
45
50
PBT
122
194
209
184
165
240
237
218
193
272
279
267
135
Tax %
28%
27%
28%
27%
23%
26%
26%
25%
25%
25%
26%
26%
25%
Net Profit
88
142
151
134
126
177
175
162
146
202
208
198
101
EPS in Rs
5.66
9.19
9.72
8.62
8.13
11.39
11.24
10.45
9.36
12.96
13.27
12.63
6.31
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
1,144
1,210
1,344
1,408
1,643
1,775
2,043
2,424
3,149
3,484
3,918
4,148
Expenses
964
1,004
1,112
1,191
1,337
1,397
1,482
1,881
2,454
2,587
2,886
3,040
Operating Profit
180
206
232
218
306
378
560
543
696
897
1,032
1,107
OPM %
16%
17%
17%
15%
19%
21%
27%
22%
22%
26%
26%
27%
Other Income
11
58
50
37
41
41
112
39
10
37
38
33
Interest
7
11
5
3
5
3
7
5
36
44
12
6
Depreciation
39
41
47
57
56
66
69
73
114
138
171
182
PBT
146
212
230
194
287
349
597
505
555
752
887
952
Tax %
31%
23%
20%
28%
32%
22%
25%
24%
26%
26%
26%
26%
Net Profit
100
163
184
139
194
272
449
386
410
553
660
709
EPS in Rs
5.92
9.58
10.85
8.27
12.06
17.6
28.98
24.93
26.48
35.61
42.36
44.18
Div. Payout %
118%
26%
5%
12%
21%
31%
28%
33%
34%
34%
37%
50%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
17
17
17
17
16
15
15
15
15
16
16
16
Reserves
978
1,167
1,347
1,425
1,464
1,420
1,794
2,119
2,465
2,908
3,418
4,143
Borrowings
127
193
49
29
26
29
45
55
572
378
28
4
Other Liabilities
365
270
262
294
286
349
376
412
495
687
804
799
Total Liabilities
1,487
1,648
1,674
1,765
1,792
1,814
2,231
2,601
3,547
3,988
4,265
4,962
Fixed Assets
329
440
679
640
621
651
634
1,277
1,901
2,004
1,968
1,885
CWIP
55
135
4
17
15
16
26
19
55
76
63
74
Investments
552
479
411
434
457
403
678
13
206
388
345
765
Other Assets
552
594
580
674
699
743
894
1,293
1,385
1,519
1,889
2,237
Total Assets
1,487
1,648
1,674
1,765
1,792
1,814
2,231
2,601
3,547
3,988
4,265
4,962
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
127
140
201
123
194
276
315
170
626
801
902
704
Investing
-112
-26
-45
-21
-28
24
-231
2
-962
-404
-296
-586
Financing
-1
-100
-184
-60
-156
-306
-87
-138
357
-385
-580
-123
Net Cash Flow
13
15
-28
43
11
-6
-3
34
20
11
27
-5
Free Cash Flow
56
-63
48
94
153
205
315
-529
-138
540
783
623
CFO/OP
91
94
107
75
85
97
81
56
104
104
107
87
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
84
82
72
78
68
71
70
84
67
72
76
69
Inventory Days
122
146
138
145
149
159
181
178
134
155
147
192
Days Payable
63
71
68
75
72
97
97
97
75
110
114
110
Cash Conversion Cycle
143
158
142
148
146
133
153
164
127
117
109
151
Working Capital Days
16
38
75
93
91
81
91
122
81
55
79
126
ROCE %
13%
15%
14%
11%
18%
23%
33%
23%
22%
25%
26%
25%

Shareholding Pattern

As of Mar 2026
Promoters 48.80%
DIIs 21.38%
FIIs 16.33%
Public 13.48%
Total 99.99%
  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
53.91%
53.86%
53.83%
53.78%
53.77%
53.74%
53.66%
47.84%
47.73%
47.56%
47.55%
48.80%
FIIs
9.53%
10.05%
10.35%
11.06%
12.17%
13.63%
14.64%
18.30%
17.77%
15.31%
14.88%
16.33%
DIIs
18.65%
18.58%
18.53%
18.38%
17.61%
16.81%
16.40%
18.71%
19.62%
22.83%
23.35%
21.38%
Government
0.00%
0.00%
0.00%
0.01%
0.00%
0.01%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
17.90%
17.50%
17.27%
16.78%
16.42%
15.80%
15.29%
15.13%
14.87%
14.31%
14.21%
13.48%
No. of Shareholders
55,965
60,817
63,230
63,892
66,953
62,743
62,081
63,948
70,064
71,957
69,338
74,043

Documents

1
Concall - Sep 2019 Sep 2019
2
Concall - Feb 2020 Feb 2020
3
Concall - Jun 2020 Jun 2020
4
Concall - Nov 2020 Nov 2020
5
Concall - Feb 2021 Feb 2021

Frequently Asked Questions about J B Chemicals & Pharmaceuticals Ltd

What does J B Chemicals & Pharmaceuticals Ltd do?
J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals g...
Where is J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) listed?
J B Chemicals & Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: JBCHEPHARM and BSE: 506943. You can view its live share price, financials, and ratios on Tapetide.
Which sector does J B Chemicals & Pharmaceuticals Ltd belong to?
J B Chemicals & Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the PE ratio of J B Chemicals & Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of J B Chemicals & Pharmaceuticals Ltd is 53.33. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of J B Chemicals & Pharmaceuticals Ltd?
Over the past 52 weeks, J B Chemicals & Pharmaceuticals Ltd has traded between a low of ₹1,627 and a high of ₹2,510. This range helps investors understand the stock's price volatility and recent trading levels.
Does J B Chemicals & Pharmaceuticals Ltd pay dividends?
Yes, J B Chemicals & Pharmaceuticals Ltd has a dividend yield of 0.91%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of J B Chemicals & Pharmaceuticals Ltd?
J B Chemicals & Pharmaceuticals Ltd has a Return on Equity (ROE) of 0.00%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research J B Chemicals & Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view J B Chemicals & Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]

Website jbpharma.com
Listed 2003-04-29
Face Value ₹ 1
Issued Size 15,66,50,956

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List